Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.68EUR
3:12pm BST
Change (% chg)

€0.02 (+0.35%)
Prev Close
€5.66
Open
€5.65
Day's High
€5.78
Day's Low
€5.65
Volume
48,793
Avg. Vol
185,270
52-wk High
€9.44
52-wk Low
€4.41

Latest Key Developments (Source: Significant Developments)

Innate Pharma Enrolls Patient In IPH4102 TELLOMAK Phase II Study
Thursday, 6 Jun 2019 

June 6 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA ENROLLS FIRST PATIENT IN IPH4102 TELLOMAK PHASE II STUDY.TELLOMAK TRIAL DESIGN AND PRECLINICAL DATA IN PTCL WILL BE PRESENTED AT INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML), JUNE 18-22.TELLOMAK IS A PHASE II STUDY TO EVALUATE EFFICACY OF IPH4102 IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMA.  Full Article

Innate Pharma Q1 Cash Position Amounted To 237.1 Million Euros
Wednesday, 15 May 2019 

May 15 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA FIRST QUARTER 2019 REPORT.Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 237.1 MILLION.IPH5401 DOSE-ESCALATION STUDY IS ON TRACK; SAFETY UPDATE AND COHORT EXPANSION EXPECTED IN 2H2019.COMMITTED TO EXECUTE ON OUR CLINICAL PLANS AND WILL PROVIDE DATA UPDATES ON MANY OF OUR PROGRAMS THROUGHOUT REST OF YEAR AND INTO 2020.  Full Article

Innate Pharma Announces Updated Results On IPH4102
Monday, 3 Dec 2018 

Dec 4 (Reuters) - INNATE PHARMA ::ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME.DIFFERENTIATING PROFILE OF IPH4102 CONFIRMED: HIGH AND DURABLE RESPONSE, FAVORABLE SAFETY PROFILE WITH LONG-TERM FOLLOW-UP AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE.EXPECTS TO INITIATE A GLOBAL PHASE II STUDY ("TELLOMAK") IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS IN THE FIRST HALF OF 2019.  Full Article

Innate Pharma Reports Business Update
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Innate Pharma SA ::INNATE PHARMA REPORTS FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.  Full Article

Innate Pharma H1 Operating Loss 15.7 Million Euros
Friday, 14 Sep 2018 

Sept 14 (Reuters) - INNATE PHARMA SA ::H1 REVENUE EUR 23.7 MILLION VERSUS EUR 21.3 MILLION YEAR AGO.H1 OPERATING LOSS EUR 15.7 MILLION V LOSS OF EUR 18.2 MILLION YEAR AGO.H1 NET LOSS EUR 16.1 MILLION VERSUS LOSS OF EUR 23.4 MILLION YEAR AGO.  Full Article

Innate H1 Net Loss At EUR 16.2 MLN
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Innate Pharma SA ::REG-INNATE PHARMA REPORTS FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.CASH POSITION EUR 141.6M (MILLION EUROS) AS OF JUNE 30, 2018.NEW CLINICAL AND TRANSLATIONAL DATA FOR MONALIZUMAB AND IPH4102 TO BE PRESENTED AT UPCOMING MEDICAL CONFERENCES.H1 REVENUE AND OTHER INCOME AMOUNTING TO EUR 23.7M (EUR 21.2M FOR FIRST HALF OF 2017).A NET LOSS FOR FIRST HALF OF 2018 AMOUNTING TO EUR 16.2M (EUR 16.6M FOR FIRST HALF OF 2017)..  Full Article

Innate Pharma Observes Preliminary Activity Of Monalizumab And Durvalumab Combination In Colorectal Cancer Patients
Thursday, 17 May 2018 

May 17 (Reuters) - INNATE PHARMA SA ::PRELIMINARY ACTIVITY OBSERVED OF THE COMBINATION OF MONALIZUMAB AND DURVALUMAB IN PATIENTS WITH COLORECTAL CANCER.3 PARTIAL RESPONSES (PR) AND 11 STABLE DISEASE (SD) RESPONSE AMONG 37 PATIENTS EVALUABLE FOR EFFICACY.DISEASE CONTROL RATE (DCR) AT 16 WEEKS WAS 24%.MANAGEABLE TOXICITY PROFILE DEMONSTRATED.  Full Article

Innate Pharma Q1 Revenue At EUR 8.7 Million
Wednesday, 16 May 2018 

May 16 (Reuters) - Innate Pharma SA ::REG-INNATE PHARMA : FIRST QUARTER 2018 REPORT.END Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 153.8 MILLION.SIGNIFICANT MOMENTUM ACROSS PORTFOLIO.Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 153.8 MILLION.REVENUES FOR Q1 OF 2018 AMOUNTED TO EUR 8.7 MILLION (EUR 7.8 MILLION FOR SAME PERIOD IN 2017).  Full Article

Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros
Thursday, 8 Mar 2018 

March 8 (Reuters) - INNATE PHARMA SA ::FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO.FY OPERATING LOSS EUR 40.0‍​ MILLION VERSUS INCOME EUR 7.6 MILLION YEAR AGO.FY NET LOSS EUR 48.4‍​ MILLION VERSUS INCOME EUR 12.6 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTED TO EUR 176.6 MILLION AS OF DEC. 31.IPH5401 WILL ENTER FIRST CLINICAL STUDIES IN ONCOLOGY IN 2018.EXPECTS CLINICAL READ-OUTS FOR BOTH MONALIZUMAB AND IPH4102 PROGRAM IN 2018.  Full Article

Eric Vivier Joins Innate Pharma As Chief Scientific Officer
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.  Full Article